Targeting tumors that lack methylthioadenosine phosphorylase (MTAP) activity: Current strategies
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Many solid tumors and hematologic malignancies lack expression of the enzyme methylthioadenosine phosphorylase (MTAP), due either to deletion of the MTAP gene or to methylation of the MTAP promoter. In cells that have MTAP, its natural substrate, methylthioadenosine (MTA), generated during polyamine biosynthesis, is cleaved to adenine and 5-methylthioribose-1-phosphate. The latter compound is further metabolized to methionine. Adenine and methionine are further metabolized and hence salvaged. In MTAP-deficient cells, however, MTA is not cleaved and the salvage pathway for adenine and methionine is absent. As a result, MTAP-deficient cells are more sensitive than MTAP-positive cells to inhibitors of de novo purine synthesis and to methionine deprivation. The challenge has been to take advantage of MTAP deficiency, and the changes in metabolism that follow, to design a strategy for targeted treatment. In this review, the frequency of MTAP-deficiency is presented and past and recent strategies to target such deficient cells are discussed, including one in which MTA is administered, followed by very high doses of a toxic purine or pyrimidine analog. In normal host cells, adenine, generated from MTA, blocks conversion of the analog to its toxic nucleotide. In MTAP-deficient tumor cells, conversion proceeds and the tumor cells are selectively killed. Successful mouse studies using this novel strategy were recently reported.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hustinx, S. R., Hruban, R. H., Leoni, L. M., Iacobuzio-Donahue, C., Cameron, J. L., Yeo, C. J., Brown, P. N., Argani, P., Ashfaq, R., Fukushima, N., et al. (2005) · Cancer Biology & Therapy · doi:10.4161/cbt.4.1.1380 · Cited by 90
Kindler, H. L., Burris, H. A., Sandler, A. B., & Oliff, I. A. (2009) · Investigational New Drugs · doi:10.1007/s10637-008-9160-1 · Cited by 79 · cited 6×
“MTAP gene deletions were also noted in 9 of 54 ampullary cancers and 4 of 33 biliary cancers.5 In another series, MTAP deficiency was found in 10 of 28 biliary tract cancers.16 In all of these solid tumors, loss of MTAP protein expression, detected by a monoclonal anti-MTAP antibody, was associated with loss of p16 pr…”
BackgroundResultInfluentialHarasawa, H., Yamada, Y., Kudoh, M., Sugahara, K., Soda, H., Hirakata, Y., Sasaki, H., Ikeda, S., Matsuo, T., Tomonaga, M., et al. (2002) · Leukemia · doi:10.1038/sj.leu.2402570 · Cited by 45
Research works printed but not linked: 47
- 10.1007/978-1-4684-5637-0_16 · doi:10.1007/978-1-4684-5637-0_16
- Chen ZH, 1996, Cancer Res, 56, 1083
- Illei PB, 2003, Clin Cancer Res, 9, 2108
- 10.1016/j.lungcan.2008.04.019 · DOI
- García-Castellano JM, 2002, Clin Cancer Res, 8, 782
- Miyazaki S, 2007, Int J Oncol, 5, 1069
- 10.1016/j.cancergencyto.2005.10.009 · doi:10.1016/j.cancergencyto.2005.10.009
- 10.1007/s12253-008-9113-1 · DOI
- Nobori T, 1991, Cancer Res, 51, 3193
- 10.1158/1078-0432.CCR-09-1511 · DOI
- 10.1159/000009983 · DOI
- 10.1097/01.pas.0000170349.47680.e8 · DOI · Paper page
- 10.1002/path.2679 · DOI
- 10.1158/1535-7163.MCT-05-0103 · DOI · Paper page
- 10.1016/S0002-9440(10)63695-4 · DOI
- 10.1038/sj.onc.1202205 · DOI
- Ishii M, 2005, Int J Oncol, 26, 985
- 10.1124/mol.52.5.903 · DOI
- 10.1016/0006-2952(83)90396-9 · doi:10.1016/0006-2952(83)90396-9
- 10.1038/sj.leu.2401771 · DOI
- Traweek ST, 1988, Blood, 71, 1568, 10.1182/blood.V71.6.1568.1568 · doi:10.1182/blood.v71.6.1568.1568
- 10.1002/(SICI)1097-0215(19980105)75:1<51::AID-IJC9>3.0.CO;2-0 · DOI · Paper page
- 10.1002/(SICI)1098-2264(199805)22:1<72::AID-GCC10>3.0.CO;2-K · DOI
- Mirebeau D, 2006, Haematologica, 91, 881
- 10.1158/1078-0432.CCR-05-2780 · doi:10.1158/1078-0432.ccr-05-2780
- 10.1158/0008-5472.CAN-09-0145 · DOI · Paper page
- 10.1016/j.cancergencyto.2010.03.002 · doi:10.1016/j.cancergencyto.2010.03.002
- Hori H, 1996, Cancer Res, 56, 5653
- 10.1073/pnas.82.15.4881 · DOI · Paper page
- 10.1126/science.273.5278.1109 · DOI · Paper page
- 10.1097/00000421-198304000-00009 · DOI
- 10.1097/00000421-198410000-00030 · DOI
- Creagan ET, 1983, Cancer Treat Rep, 67, 1047
- 10.1007/BF00194553 · DOI
- 10.1158/1535-7163.MCT-06-0343 · DOI · Paper page
- Tan CT, 1994, J Clin Oncol, 12, 1955, 10.1200/JCO.1994.12.9.1955 · doi:10.1200/jco.1994.12.9.1955
- 10.1158/1078-0432.CCR-04-0972 · DOI
- 10.1016/S0168-8278(00)00078-7 · DOI
- Wolford RW, 1984, Exp Hematol, 12, 867
- 10.1002/ana.20895 · DOI
- 10.1186/1471-2407-10-265 · DOI
- 10.1124/mol.108.054411 · DOI
- 10.1073/pnas.78.2.1219 · DOI
- 10.1371/journal.pone.0005735 · DOI
- Lubin M, 2009, Proc Am Assoc Cancer Res, 4, e5735
- 10.1002/1097-0142(195611/12)9:6<1092::AID-CNCR2820090605>3.0.CO;2-1 · doi:10.1002/1097-0142(195611/12)9:6<1092::aid-cncr2820090605>3.0.co;2-1
- Bertino JR, 2010, Proc Am Assoc Cancer Res, 5393
Cited by
Polyamine metabolism and cancer: treatments, challenges and opportunities
Casero, R. A., Murray Stewart, T., & Pegg, A. E. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0050-3 · Cited by 817
MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells
Kryukov, G. V., Wilson, F. H., Ruth, J. R., Paulk, J., Tsherniak, A., Marlow, S. E., Vazquez, F., Weir, B. A., Fitzgerald, M. E., Tanaka, M., et al. (2016) · Science · doi:10.1126/science.aad5214 · Cited by 688
S-adenosylmethionine in Liver Health, Injury, and Cancer
Lu, S. C., & Mato, J. M. (2012) · Physiological Reviews · doi:10.1152/physrev.00047.2011 · Cited by 554
Regulation of cancer cell metabolism: Oncogenic MYC in the driver’s seat
Dong, Y., Tu, R., Liu, H., & Qing, G. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00235-2 · Cited by 405
The old and new biochemistry of polyamines
Bae, D.-H., Lane, D. J. R., Jansson, P. J., & Richardson, D. R. (2018) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2018.06.004 · Cited by 205
Metadata
- Authors
- Bertino, J. R., Waud, W. R., Parker, W. B., & Lubin, M.
- Venue
- Cancer Biology & Therapy
- Publisher
- Informa UK Limited
- Published
- 2011-04
- Volume
- 11
- Issue
- 7
- Pages
- 627-632
- ISSN
- 1538-4047 (ISSN-L)
- 1555-8576
- OpenAlex
- W2047073318
- Cited by
- 150
- References
- 3
- FWCI
- 2.47
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting tumors that lack methylthioadenosine phosphorylase (MTAP) activity: Current strategies. https://app.cochat.ai/papers/10.4161/cbt.11.7.14948
- The paper
- Bertino, J. R., Waud, W. R., Parker, W. B., & Lubin, M. (2011). Targeting tumors that lack methylthioadenosine phosphorylase (MTAP) activity: Current strategies. Cancer Biology & Therapy. https://doi.org/10.4161/cbt.11.7.14948
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.